title: Fluctuating parkinsonism: a pilot study of single afternoon dose of levodopa methyl ester.
abstract: Thirty-four patients with idiopathic fluctuating Parkinson's disease and early afternoon "delayed on" or severely resistant "off" periods, in spite of long-term antiparkinsonian therapy, were studied. The first afternoon levodopa administration was substituted with an equimolar dosage of the liquid formulation levodopa methyl ester (LDME). The major end-points for efficacy were latency to "on" and duration of "on" periods. The patients were divided into five subgroups according to their baseline treatment and they were evaluated monthly for 6 months using the Unified Parkinson's Disease Rating Scale. The patients completed weekly self-evaluation using an "on-off" chart. LDME was well tolerated by all the patients. A statistically significant reduction in latency to "on" was observed in all patients. The clinical effect of LDME remained stable during the treatment period (repeat measures ANOVA). The more rapid clinical effect of LDME and its stable and predictable antiparkinsonian activity represents a new and useful approach for treating patients with complicated Parkinson's disease.
authors: Department of Neurosciences, University La Sapienza, Rome, Italy.
authors: F
authors: F
authors: Stocchi
authors: L
authors: L
authors: Barbato
authors: L
authors: L
authors: Bramante
authors: G
authors: G
authors: Nordera
authors: L
authors: L
authors: Vacca
authors: S
authors: S
authors: Ruggieri
mesh_terms: D000284:Administration, Oral; D000368:Aged; D000704:Analysis of Variance; D000978:Antiparkinson Agents / Q000008:administration & dosage* / Q000009:adverse effects; D002940:Circadian Rhythm / Q000502:physiology*; D003692:Delayed-Action Preparations; D018491:Dopamine Agonists / Q000008:administration & dosage / Q000009:adverse effects; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005069:Evaluation Studies as Topic; D005260:Female; D006801:Humans; D007263:Infusions, Parenteral; D007980:Levodopa / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D008297:Male; D008875:Middle Aged; D010300:Parkinson Disease / Q000188:drug therapy* / Q000503:physiopathology; D010865:Pilot Projects
chemical_list: D000978:Antiparkinson Agents; D003692:Delayed-Action Preparations; D018491:Dopamine Agonists; D007980:Levodopa; C035420:levodopa methyl ester